Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed

Colorectal Cancer Clinical Trial

Official title:

Phase III Intergroup Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection, Followed by 5-FU/Leucovorin for Patients With Colon Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00002525
• Other study ID #: E1292
• Secondary ID: E1292U10CA023318
• Status: Terminated
• Phase: Phase 3
• Start date: October 1, 1993
• Est. completion date: April 2015

Study information

• Verified date: June 2023
• Source: Eastern Cooperative Oncology Group
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells. It is not yet known if surgery is more effective with or without chemotherapy for colon cancer. PURPOSE: Randomized phase III trial to evaluate whether perioperative 5-Fluorouracil (5-FU) chemotherapy after curative resection could improve overall survival and disease-free survival in patients with Duke's B3 or C colon cancer.

Description:

OBJECTIVES: I. To determine if adjuvant therapy with one week of continuous 5-FU given within 24 hours of a curative colon resection followed by 6 months of 5-FU/leucovorin is effective in prolonging the disease-free survival and increasing overall survival in patients with Dukes' B3 or C colon cancer, when compared to patients who are treated with 5-FU/leucovorin only. II. 1. To determine if a week of perioperative continuous 5-FU affects disease-free survival and overall survival in patients with Dukes' B2 colon cancer. OUTLINE: This is an open-label, randomized phase III study. Patients undergo curative colon resection via laparotomy. Patients are randomized to 1 of 2 arms in a 1:1 ratio. Arm I (Perioperative 5-FU): Within 24 hours of the colon resection, patients receive perioperative 5-fluorouracil (5-FU) intravenously (IV) over 24 hours for 7 days. Arm II (No perioperative 5-FU): Patients receive no perioperative fluorouracil. After surgery, patients with stage I, stage IIA, or stage IV colon cancer are immediately removed from study. Patients with stage IIB, IIC, or III colon cancer are re-registered within 35 days postoperatively. Beginning 21-35 days after surgery, patients with stage IIC or III disease receive leucovorin calcium IV bolus immediately followed by 5-FU IV bolus on days 1-5. Courses repeat every 28 days for a total of 6 courses in the absence of disease progression or unacceptable toxicity. Patients with stage IIB disease do not receive adjuvant 5-FU and leucovorin calcium. Patients are followed every 3 months for 2 years, then every 6 months for 2 years, and then annually until 15 years. PROJECTED ACCRUAL: A total of 800-2,000 patients (at least 400 per treatment arm) will be accrued for this study over 2-3 years.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 859
• Est. completion date: April 2015
• Est. primary completion date: February 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Eligibility Criteria for Randomization:

Inclusion Criteria:

• Adenocarcinoma of the colon documented by colonoscopy or barium enema
• Tumor either considered resectable or totally resected within 24 hours prior to study
• Randomization within 2 weeks prior to surgery or within 24 hours after surgery required
• Patients randomized after surgery must meet the following criteria:
• Complete resection performed with no evidence of residual disease or distant metastases
• Distal margin of tumor above the peritoneal reflection in area of rectum
• No free perforation Intestinal obstruction allowed
• Preliminary or complementary colostomy allowed
• Concurrent registration for E3293 strongly recommended
• Age 18 and over
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
• Adequate organ function based on the following tests within 2 weeks prior to randomization
• White Blood Cell (WBC) at least 3,000/mm^3
• Platelet count at least 100,000/mm^3
• Bilirubin no greater than 2.0 mg/dL
• Creatinine no greater than 2.0 mg/dL
• No second malignancy within 5 years except: superficial non-melanomatous skin cancer and carcinoma in situ of the cervix
• Fertile patients must use adequate contraception

Exclusion Criteria:

• Dual primary tumors
• Prior nonmalignant systemic disease that would preclude use of chemotherapy
• Pregnant or nursing
• Prior fluorouracil
• Other prior or concurrent chemotherapy for this malignancy
• Prior or concurrent radiotherapy for this malignancy

Eligibility Criteria for Re-registration for Patients Randomized Pre-operatively:

• Must have pathologic classification of Dukes' B2, B3, or C disease by the contributing institution.
• Must be re-registered < 35 days after surgery.
• ECOG performance status of 0-2.
• Complete resection must have been performed with no evidence of residual disease or distant metastasis.
• Distal margin of the tumor must not extend below the peritoneal reflection in the area of the rectum.
• Single primary colon carcinoma without free perforation demonstrated. Patients with intestinal obstruction are eligible. Preliminary or complementary colostomy dose not preclude entry of a patient.
• Have WBC > 3000/mm^3, platelets > 100,000/mm^3, adequate renal (serum creatinine <= 2.0mg/dL) and hepatic function (bilirubin <= 2.0mg/dL), within one week prior to beginning adjuvant chemotherapy (For Dukes' B3 and C patients only).

Eligibility Criteria for Re-registration for Patients Randomized Post-operatively:

• Must have pathologic classification of Dukes' B2, B3, or C disease by the contributing institution.
• Patient must be re-registered < 35 days after surgery.
• ECOG performance status of 0-2.
• Started perioperative 5-FU, if assigned, within 24 hours of surgery.
• Have WBC > 3000/mm^3, platelets > 100,000/mm^3, adequate renal (serum creatinine <= 2.0mg/dL) and hepatic function (bilirubin < =2.0mg/dL), within one week prior to beginning adjuvant chemotherapy (For Dukes' B3 and C patients only).

Related Conditions & MeSH terms

• Colonic Neoplasms
• Colorectal Cancer

Intervention

Drug:
• fluorouracil
Perioperative 5-FU: 600 mg/m^2/d x 7 days continuous IV, beginning within 24 hours of surgery After surgery, 5-FU was given 425 mg/m^2 IV push on days 1-5
• leucovorin calcium
given after surgery at dose of 20mg/m^2 IV push on days 1-5

Locations

Country	Name	City	State
United States	Loyola University Medical Center	Maywood	Illinois

Sponsors (6)

Lead Sponsor	Collaborator
ECOG-ACRIN Cancer Research Group	American College of Surgeons, Cancer and Leukemia Group B, National Cancer Institute (NCI), NSABP Foundation Inc, SWOG Cancer Research Network

Country where clinical trial is conducted

United States, 

References & Publications (1)

Kemeny M, Ibrahim J, Benson AB, et al.: Post-operative complications of continuous infusion 5 FU following curative resection of colon cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 16: A923, 260a, 1997.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	5-year Overall Survival Rate in Patients With Dukes' B3/C Disease	Overall survival (OS) is defined as time from randomization to death from any cause or last date known alive. Kaplan-Meier method was used to estimate 5-year OS rate	every 3 months for 2 years, then every 6 months for 2 years, and then annually until year 15 after randomization
Secondary	5-year Disease-free Survival Rate in Patients With Dukes' B3/C Disease	Disease-free survival (DFS) was defined as time from randomization to recurrence, second invasive primary cancer, or deaths, whichever occurred first. Patients who were still alive and had no DFS events were censored at the last disease assessment date known to be free of DFS events. Patients without any follow up data were censored at random assignment. Kaplan-Meier method was used to estimate the 5-year DFS rate.	every 3 months for 2 years, then every 6 months for 2 years, and then annually until year 15 after randomization
Secondary	5-year Overall Survival Rate in Patients With Dukes' B2 Disease	Overall survival (OS) is defined as time from randomization to death from any cause or last date known alive. Kaplan-Meier method was used to estimate 5-year OS rate	every 3 months for 2 years, then every 6 months for 2 years, and then annually until year 15 after randomization
Secondary	5-year Disease-free Survival Rate in Patients With Dukes' B2 Disease	Disease-free survival (DFS) was defined as time from randomization to recurrence, second invasive primary cancer, or deaths, whichever occurred first. Patients who were still alive and had no DFS events were censored at the last disease assessment date known to be free of DFS events. Patients without any follow up data were censored at random assignment. Kaplan-Meier method was used to estimate the 5-year DFS rate.	every 3 months for 2 years, then every 6 months for 2 years, and then annually until year 15 after randomization